Wegovy Side Effects: What Happens to Your Body When You Stop Semaglutide

Does Wegovy Cause a True Withdrawal Syndrome?

The short answer: Wegovy does not produce physical dependence or a classical withdrawal syndrome the way opioids or benzodiazepines do. Semaglutide has no known action on addiction pathways that generates physiological withdrawal upon cessation. What it does produce is a sharp reversal of its pharmacological effects, and for many women that reversal feels significant.

When semaglutide leaves your system (its half-life is approximately one week), the appetite suppression it was providing disappears. Gastric emptying speeds back up. GLP-1 receptor signaling in the hypothalamus, which had been blunting hunger signals, returns to baseline. The result is not a toxidrome. It is the return of the biological state that existed before treatment, often felt more acutely because your set-point physiology has not yet adjusted to a lower body weight.

What Women Report After Stopping

Post-market surveillance and clinical trial extension data describe a recognizable cluster of experiences after discontinuation:

• A rapid return of hunger, often described as more intense than before starting the drug
• Food cravings, particularly for high-calorie, high-carbohydrate foods
• Fatigue, especially in the first two to four weeks
• Mood changes, including low mood or irritability in some women
• Nausea resolution (a welcome change for many)
• Rebound weight gain beginning within the first four weeks

The FDA label for Wegovy does not list a formal withdrawal syndrome as an adverse event, but FAERS (FDA Adverse Event Reporting System) post-market data include reports of rebound appetite, mood disturbance, and fatigue following discontinuation.

How Fast Does Semaglutide Clear?

Semaglutide's elimination half-life is approximately 7 days, meaning it takes roughly five half-lives, about 35 days, for the drug to clear your system substantially. Pharmacological effects on appetite and gastric motility begin to wane before full clearance, typically within the first one to two weeks of the last injection. Women planning to stop should factor this timeline into any perioperative, pregnancy, or medication-change planning.

The STEP Trials: What the Clinical Data Show About Stopping Wegovy

The most direct evidence for what happens when women stop Wegovy comes from the STEP 4 trial, a randomized withdrawal study published in JAMA in 2021.

STEP 4 Trial Design and Key Findings

STEP 4 enrolled 803 adults who had already lost weight on semaglutide 2.4 mg over 20 weeks. Participants were then randomized to continue semaglutide or switch to placebo for an additional 48 weeks. The results were striking.

• The continued-semaglutide group lost an additional 7.9% of body weight over the maintenance phase.
• The placebo (discontinuation) group regained 6.9% of body weight, for a net change of plus 6.9 percentage points relative to the continuation group.
• By week 68 of the total study, those who had stopped semaglutide had regained approximately two-thirds of their previously lost weight.

Cardiometabolic improvements also reversed: waist circumference increased, blood pressure rose, and blood glucose climbed back toward pre-treatment levels in those who stopped.

STEP 1 Extension Data

The STEP 1 trial and its one-year extension confirm the same pattern. After stopping semaglutide at week 68, participants regained most lost weight by week 120. Cardiovascular risk markers that had improved, including C-reactive protein and lipid panels, also partially reversed.

The STEP investigators noted that this weight regain trajectory supports the view that obesity is a chronic, relapsing condition requiring ongoing treatment, not a problem that is solved by a finite course of medication.

Women-Specific Effects of Stopping Wegovy

The rebound effects of stopping semaglutide are not gender-neutral. Female physiology, hormonal status, and life stage all shape what happens when the drug is withdrawn. Below is a life-stage framework that does not appear in the STEP trial publications or existing patient-facing content.

Reproductive Years (Ages 18-40)

In women of reproductive age, semaglutide often improves insulin sensitivity, reduces androgen levels, and in some women restores more regular menstrual cycles, particularly those with PCOS. A small prospective study published in Frontiers in Endocrinology found that GLP-1 receptor agonists reduced free androgen index and improved cycle regularity in women with PCOS.

After stopping Wegovy, these hormonal benefits may reverse over weeks to months, particularly if significant weight is regained. Women with PCOS should discuss a monitoring plan with their clinician before stopping. Cycle irregularity may return, and acne or hirsutism symptoms may worsen as androgen levels rise again with increasing adiposity.

One additional issue: weight loss on semaglutide can restore or improve fertility in women who had ovulatory dysfunction due to obesity or PCOS. Stopping the drug while sexually active without reliable contraception carries a real pregnancy risk, because conception may occur before the woman realizes her fertility has returned.

Perimenopause (Typically Ages 44-52)

Perimenopausal women face a compounded rebound. Declining estrogen already shifts fat distribution toward visceral and abdominal depots. Stopping semaglutide on top of this hormonal shift accelerates that redistribution. The combination of estrogen decline and appetite rebound may produce faster and more abdominal-predominant weight regain than in younger women.

No dedicated clinical trial has examined semaglutide discontinuation specifically in perimenopausal women, a gap in the evidence that the WomanRx editorial board considers clinically significant. What is extrapolated from general trial data may underestimate the magnitude of rebound in this group.

Postmenopause

Postmenopausal women in the STEP trials were not analyzed as a separate sub-group in published discontinuation data, which is an evidence gap. The general pattern of two-thirds weight regain within one year applies to the mixed adult population studied. Given that postmenopausal women have lower resting metabolic rates and altered adipokine profiles, the trajectory of regain may differ from younger cohorts, but direct data are lacking.

Rare and Serious Side Effects to Know Before Stopping

Some side effects of Wegovy do not disappear when you stop the drug. They may persist or require monitoring even after your last injection.

Pancreatitis

Acute pancreatitis is listed as a warning in the Wegovy prescribing information. The incidence in STEP trials was low (approximately 0.2% vs 0.1% placebo), but pancreatitis can be severe. If you were diagnosed with pancreatitis during treatment, it is a reason not to restart semaglutide.

Thyroid C-Cell Tumors

The Wegovy label carries a Boxed Warning for thyroid C-cell tumors based on rodent studies. The drug is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). If you have an elevated calcitonin level discovered during treatment, your clinician should continue to monitor this after stopping, given the drug's long half-life and cumulative exposure.

Gallbladder Disease

Rapid weight loss, including weight loss on GLP-1 medications, is a recognized risk factor for gallstone formation and cholecystitis. In the STEP 1 trial, cholelithiasis occurred in 1.6% of semaglutide-treated participants vs 0.7% of the placebo group. Symptoms of gallbladder disease do not necessarily resolve after stopping the drug if gallstones have already formed.

Gastrointestinal Symptoms

Nausea, vomiting, diarrhea, and constipation are the most common side effects of Wegovy, occurring in up to 44% of users for nausea in the first months. These typically improve during treatment and resolve after stopping. They are not a reason to abruptly discontinue without medical guidance; a dose reduction is usually the first step.

Diabetic Retinopathy Complication

The label notes a risk of diabetic retinopathy complications in people with type 2 diabetes treated with semaglutide, likely related to rapid glucose lowering. If you have diabetes and were taking Wegovy off-label for glucose management alongside your primary diabetes treatment, your clinician should monitor retinal status after stopping.

Pregnancy, Lactation, and Contraception: A Required Conversation Before You Stop

Wegovy is contraindicated in pregnancy. This is not a precaution. The FDA label states that semaglutide should be discontinued at least two months before a planned pregnancy, because of the drug's long half-life and because animal reproduction studies showed fetal harm at clinically relevant exposures.

What the Human Data Show

Human data on semaglutide exposure in pregnancy are limited to case reports and small post-market series. No randomized trial has examined semaglutide in pregnant women. ACOG recommends that GLP-1 receptor agonists be discontinued before conception. Animal data in rats and rabbits showed embryofetal toxicity (structural malformations, fetal growth restriction) at exposures below the human therapeutic dose. Until strong human safety data exist, the evidence gap is significant and the precautionary approach is justified.

Fertility Recovery and the Contraception Gap

As noted above, semaglutide-associated weight loss may restore ovulation in women with anovulatory cycles. If you are stopping Wegovy but do not want to become pregnant, continue effective contraception from your last dose through at least two complete menstrual cycles, or use a method that does not depend on cycle predictability. Do not assume that your previous cycle irregularity will return immediately.

Lactation

Semaglutide transfer into human breast milk is unknown. Animal studies show low transfer into milk, but neonatal exposure and safety have not been studied in humans. The manufacturer recommends not using Wegovy while breastfeeding. If you are postpartum and considering restarting Wegovy after weaning, discuss timing with your clinician, keeping in mind that weight loss efforts can affect milk supply even in the absence of medication.

Who Should Stop Wegovy, and Who Should Think Twice

Situations Where Stopping Makes Clinical Sense

• Confirmed or planned pregnancy (stop at least 2 months before conception)
• Severe or persistent pancreatitis during treatment
• Medullary thyroid carcinoma diagnosis or suspicious calcitonin elevation
• Severe allergic reaction to semaglutide
• Intolerable gastrointestinal side effects that persist beyond dose reduction strategies
• Patient preference after shared decision-making, with full understanding of rebound

Life-Stage Considerations for Continuing vs. Stopping

Women in perimenopause approaching a metabolic inflection point may have the most to lose from stopping without a plan. The intersection of estrogen decline, visceral fat redistribution, and appetite rebound is not trivial. The Menopause Society has acknowledged the overlap between menopause and obesity management, though specific GLP-1 discontinuation guidance for this group is still evolving.

Women with PCOS who achieved cycle regularity on semaglutide should be counseled that stopping without a lifestyle bridge may result in a fairly rapid return of androgenic and metabolic features, particularly if weight is regained.

How to Stop Wegovy with the Least Disruption

There is no FDA-approved tapering protocol for semaglutide discontinuation, because the drug is not physically addictive. However, clinical practice and emerging evidence support several strategies.

Taper the Dose Before Stopping Completely

Rather than stopping cold at the full 2.4 mg dose, some clinicians step the dose back down (2.4 mg to 1.7 mg to 1.0 mg over several weeks) to allow gastric motility and appetite to adjust more gradually. This is an off-label practice, as the Wegovy label does not specify a discontinuation taper, but it is logistically feasible because the dose-escalation pen sizes exist.

Strengthen Behavioral Infrastructure Before the Last Dose

The STEP 1 extension data showed that individuals who maintained structured dietary and physical activity habits regained less weight than those who did not, though regain still occurred in nearly all participants. Starting or intensifying dietary counseling, working with a registered dietitian, and establishing consistent movement patterns before stopping gives you the best chance of a slower rebound.

Monitor Hormonal and Metabolic Markers Closely

If you have PCOS, request a repeat androgen panel, fasting insulin, and HOMA-IR approximately three months after stopping. If you are perimenopausal, track blood pressure, fasting glucose, and waist circumference monthly for at least six months. These markers tell you whether the rebound is progressing in a clinically significant direction before symptoms become obvious.

Discuss a Transition Agent with Your Prescriber

Some clinicians bridge women who must stop semaglutide (due to pregnancy planning, cost, or side effects) onto alternative agents. Metformin, for example, has a reasonable safety profile in women with PCOS and those with prediabetes, and may blunt some of the insulin-resistance rebound. Orlistat has a more established pregnancy discontinuation timeline if needed. These transitions require individualized clinical judgment, not a one-size solution.

What the Evidence Does Not Yet Tell Us

Women have been under-represented in GLP-1 clinical trials as a separately analyzed group. The STEP trials did enroll a majority of female participants (approximately 75% in STEP 1), but subgroup analyses by menopausal status, PCOS diagnosis, or reproductive history were not the primary focus of published data. The following questions remain open in the literature:

• Does the rate or magnitude of weight regain after stopping differ between premenopausal and postmenopausal women?
• What is the timeline for androgenic hormone rebound in women with PCOS after stopping semaglutide?
• Is there a meaningful difference in mood or depressive symptom trajectory after discontinuation in women with perimenopause-related mood instability?
• Does prior use of hormonal contraception or menopausal hormone therapy modify the appetite-rebound response?

The WomanRx editorial board recommends that clinicians document PCOS status, menopausal status, and hormonal contraception use for all female patients initiating or discontinuing semaglutide, to contribute to the real-world evidence base that clinical trials have not yet provided.